Arvinas (ARVN) Other Working Capital Changes (2017 - 2026)
Arvinas (ARVN) posted quarterly Other Working Capital Changes of -$15.6 million for Q1 2026, down 3020.0% year-over-year from $534246.6 in Q1 2025, and up 93.53% quarter-over-quarter from -$241.0 million in Q4 2025.
Analysis
Arvinas (ARVN) Other Working Capital Changes (2017 - 2026) Analysis & Trends
Arvinas' Other Working Capital Changes history runs 10 years deep, the most recent figure standing at -$15.6 million for Q1 2026.
- In Q1 2026, Other Working Capital Changes fell 3020.0% year-over-year to -$15.6 million; the TTM figure through Mar 2026 stood at -$257.7 million (down 155.15% YoY), while the FY2025 annual figure was -$242.6 million, down 140.2% from the prior year.
- Other Working Capital Changes for Q1 2026 stood at -$15.6 million, up from -$241.0 million in the prior quarter.
- The five-year high for Other Working Capital Changes was $4.1 million in Q2 2024, with the low at -$6.9 million in Q1 2023.
- The 5-year median for Other Working Capital Changes is $400000.0 (2024), against an average of -$588235.3.
- The sharpest annual moves came in 2023 and 2024: Other Working Capital Changes sank 18175.0% in 2023, then surged 10200.0% in 2024.
- Arvinas' Other Working Capital Changes stood at -$400000.0 in 2022, then tumbled by 18175.0% to -$73.1 million in 2023, then plunged by 35.98% to -$99.4 million in 2024, then sank by 142.45% to -$241.0 million in 2025, then jumped by 93.53% to -$15.6 million in 2026.
- Business Quant data shows ARVN's Other Working Capital Changes at -$15.6 million in Q1 2026, -$241.0 million in Q4 2025, and $209.7 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn |
| 10 | Arvinas | 605.88 Mn | 37.98 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -189.90 Mn |
| Jun 30, 2026 | -189.90 Mn |
| Mar 31, 2026 | -15.60 Mn |
| Mar 31, 2026 | -15.60 Mn |
| Dec 31, 2025 | -9.50 Mn |
| Dec 31, 2025 | -9.50 Mn |
| Sep 30, 2025 | -21.80 Mn |
| Sep 30, 2025 | -21.80 Mn |
| Jun 30, 2025 | -22.40 Mn |
| Jun 30, 2025 | -22.40 Mn |
| Mar 31, 2025 | -188.90 Mn |
| Mar 31, 2025 | -188.90 Mn |
| Dec 31, 2024 | -55.50 Mn |
| Dec 31, 2024 | -55.50 Mn |
| Sep 30, 2024 | -95.50 Mn |
| Sep 30, 2024 | -95.50 Mn |
| Jun 30, 2024 | 75.30 Mn |
| Jun 30, 2024 | 75.30 Mn |
| Mar 31, 2024 | -25.30 Mn |
| Mar 31, 2024 | -25.30 Mn |